Molecules 2014, 19(2), 2469-2480; doi:10.3390/molecules19022469
Article

Novel Lycorine Derivatives as Anticancer Agents: Synthesis and In Vitro Biological Evaluation

1,2, 3, 1, 3, 1,* email and 1,* email
Received: 29 January 2014; in revised form: 13 February 2014 / Accepted: 13 February 2014 / Published: 21 February 2014
(This article belongs to the Section Medicinal Chemistry)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Lycorine, which is the most abundant alkaloid isolated from the Amaryllidaceae family of plants, reportedly exhibits promising anticancer activities. Herein, a series of novel lycorine derivatives were synthesized and evaluated for their in vitro inhibitory activities against seven different cancer cell lines, including A549, HCT116, SK-OV-3, NCI-H460, K562, MCF-7 and HL-60. The results indicated that compounds bearing diverse amine substituents at the C-2 position demonstrated good anticancer activities. The selectivity towards different cancer cell lines of the synthesized derivatives is discussed.
Keywords: lycorine derivatives; anticancer; synthesis
PDF Full-text Download PDF Full-Text [299 KB, uploaded 18 June 2014 20:30 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Wang, P.; Yuan, H.-H.; Zhang, X.; Li, Y.-P.; Shang, L.-Q.; Yin, Z. Novel Lycorine Derivatives as Anticancer Agents: Synthesis and In Vitro Biological Evaluation. Molecules 2014, 19, 2469-2480.

AMA Style

Wang P, Yuan H-H, Zhang X, Li Y-P, Shang L-Q, Yin Z. Novel Lycorine Derivatives as Anticancer Agents: Synthesis and In Vitro Biological Evaluation. Molecules. 2014; 19(2):2469-2480.

Chicago/Turabian Style

Wang, Peng; Yuan, Hui-Hui; Zhang, Xue; Li, Yun-Ping; Shang, Lu-Qing; Yin, Zheng. 2014. "Novel Lycorine Derivatives as Anticancer Agents: Synthesis and In Vitro Biological Evaluation." Molecules 19, no. 2: 2469-2480.


Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert